Description

• Chemical name: (17β)-3-Oxoandrost-4-en-17-yl propanoate
• Formula: C₂₂H₃₂O₃
• Anabolic activity index: 100% (reference drug)
• Androgenic activity index: 100% (reference drug)

TESTOBOLIN XR 4ml x 1ml AMP - ALPHA PHARMA

Alpha-Pharma Testobolin XR is an extremely large/long ester base testosterone compound that is primarily used in the treatment of low testosterone. Comprised of Testosterone Undecanoate, this is the same hormone and ester used in the anabolic steroid Andriol, an oral testosterone capsule. However, Testobolin XR is an injectable testosterone hormone and carries a much longer activity time post administration.

Testobolin XR is a relatively new anabolic steroid that was first brought to the market in 2004 by Schering AG. It has been approved for the treatment of androgen deficiencies in most countries around the world. However, in the U.S. the pharmaceutical company Indevus owns the rights to the Testobolin XR line, and it has yet to reach full FDA approval in the U.S. That could very well change in the near future, and theres no logical reason for it not to; however, Testobolin XR has had a difficult time gaining U.S. FDA approval for reasons that are somewhat unknown.

Although primarily viewed as a testosterone compound for the treatment of low testosterone, Testobolin XR can be used for performance enhancing purposes. However, it is not all that common among athletes and gym rats due to its very slow acting nature. Results could easily be obtained with this compound similar to the more popular testosterones in Testosterone Cypionate and Testosterone Enanthate. However, due to the very slow activity, Testobolin XR won’t be well-suited for most performance based plans.
Testobolin XR is a pure testosterone hormone attached to the very large Undecanoate ester (Testosterone Undecanoate). The ester is attached to the hormone in order to regulate its release pattern, but it does not affect the testosterone hormones mode of action in anyway. The functions and traits of Testobolin XR on a hormonal basis will be the same as all testosterone compounds.

Testobolin XR, as a testosterone hormone, like all testosterone hormones carries an anabolic rating of 100 as well as an androgenic rating of 100. This is an estrogenic anabolic steroid in that it does aromatize at a fairly significant rate. As a testosterone compound, Testobolin XR will also carry one of the longest half-lives of any testosterone or anabolic steroid available. Testobolin XR carries an active half-life of approximately three months. Compare this to the more popular Testosterone Cypionate and Testosterone Enanthate, which both carry half-lives a little greater than a week and you can begin to understand how slowly acting Testobolin XR will be.

For the purpose of treating low testosterone, the primary purpose of use, standard Testobolin XR doses will normally be 1,000mg every 12 weeks. Most plans will call for a second 1,000mg dose to be applied 6 weeks after the first injection, and from there the standard 12 week protocol will follow. Thats it, thats all there is too it. Because it is such a slow and long lasting testosterone, you could actually get by and get by well with only a handful of injections per year and see your low testosterone condition vanish.

In a performance setting, most will need approximately 1,000mg every 2-4 weeks to see desired results. However, Testobolin XR truly isnt a compound well-suited for most performance plans and there are better options available.

For the purpose of treating low testosterone, Testobolin XR is one of the best options you will ever have. As an injectable testosterone, it will be far more effective than transdermal patches and creams, as well as most oral testosterone preparations. Due to the very large Undecanoate ester, it will also be very convenient due to the extremely infrequent injection schedule. Beyond these factors, Testobolin XR will work just as well, no better or worse than any other injectable testosterone commonly used to treat low testosterone. Its advantage truly is in the long active therapeutic window.